These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 2713867)
1. Levodopa and 3-O-methyldopa plasma levels in parkinsonian patients with stable and fluctuating motor response. Luquin MR; Vaamonde J; Obeso JA Clin Neuropharmacol; 1989 Feb; 12(1):46-54. PubMed ID: 2713867 [TBL] [Abstract][Full Text] [Related]
2. Increased dosage of carbidopa in parkinsonian patients on low carbidopa-levodopa regimen. Effect on levodopa bioavailability. Contin M; Riva R; Martinelli P; Procaccianti G; Baruzzi A Clin Neuropharmacol; 1989 Feb; 12(1):75-81. PubMed ID: 2713868 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease. Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409 [TBL] [Abstract][Full Text] [Related]
4. Suppression of dyskinesias in advanced Parkinson's disease. I. Continuous intravenous levodopa shifts dose response for production of dyskinesias but not for relief of parkinsonism in patients with advanced Parkinson's disease. Schuh LA; Bennett JP Neurology; 1993 Aug; 43(8):1545-50. PubMed ID: 8351009 [TBL] [Abstract][Full Text] [Related]
5. [Diurnal worsening in Parkinson patients treated with levodopa]. Piccini P; Del Dotto P; Pardini C; D'Antonio P; Rossi G; Bonuccelli U Riv Neurol; 1991; 61(6):219-24. PubMed ID: 1813974 [TBL] [Abstract][Full Text] [Related]
6. 3-O-methyldopa and motor fluctuations in Parkinson's disease. Fabbrini G; Juncos JL; Mouradian MM; Serrati C; Chase TN Neurology; 1987 May; 37(5):856-9. PubMed ID: 3574690 [TBL] [Abstract][Full Text] [Related]
7. Diurnal motor variations to repeated doses of levodopa in Parkinson's disease. Bonuccelli U; Del Dotto P; Lucetti C; Petrozzi L; Bernardini S; Gambaccini G; Rossi G; Piccini P Clin Neuropharmacol; 2000; 23(1):28-33. PubMed ID: 10682228 [TBL] [Abstract][Full Text] [Related]
8. Plasma O-methyldopa in levodopa-induced dyskinesias. A bioclinical investigation. Feuerstein C; Serre F; Gavend M; Pellat J; Perret J; Tanche M Acta Neurol Scand; 1977 Dec; 56(6):508-24. PubMed ID: 605774 [TBL] [Abstract][Full Text] [Related]
9. [The effect of controlled release of DOPA and carbidopa on clinical response and plasma pharmacokinetics of DOPA in parkinsonian patients]. García de Yébenes J; Mateo D; Pino MA; Cordero M; Pastor M; Chacón J; Morales B; Sánchez V; Mena MA; Giménez Roldán S Neurologia; 1997 Apr; 12(4):145-56. PubMed ID: 9235023 [TBL] [Abstract][Full Text] [Related]
10. Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon. Colosimo C; Merello M; Hughes AJ; Sieradzan K; Lees AJ J Neurol Neurosurg Psychiatry; 1996 Jun; 60(6):634-7. PubMed ID: 8648329 [TBL] [Abstract][Full Text] [Related]
11. Does O-methyl-dopa play a role in levodopa-induced dyskinesias? Feuerstein C; Tanche M; Serre F; Gavend M; Pellat J; Perret J Acta Neurol Scand; 1977 Jul; 56(1):79-82. PubMed ID: 878846 [TBL] [Abstract][Full Text] [Related]
12. Effect of meal timing on the kinetic-dynamic profile of levodopa/carbidopa controlled release [corrected] in parkinsonian patients. Contin M; Riva R; Martinelli P; Albani F; Baruzzi A Eur J Clin Pharmacol; 1998 Jun; 54(4):303-8. PubMed ID: 9696954 [TBL] [Abstract][Full Text] [Related]
13. Motor fluctuations during continuous levodopa infusions in patients with Parkinson's disease. Nutt JG; Carter JH; Lea ES; Woodward WR Mov Disord; 1997 May; 12(3):285-92. PubMed ID: 9159720 [TBL] [Abstract][Full Text] [Related]
14. Temporal relationships between plasma and cerebrospinal fluid pharmacokinetics of levodopa and clinical effect in Parkinson's disease. Olanow CW; Gauger LL; Cedarbaum JM Ann Neurol; 1991 May; 29(5):556-9. PubMed ID: 1859185 [TBL] [Abstract][Full Text] [Related]
15. Complexity of motor response to different doses of duodenal levodopa infusion in Parkinson disease. Nyholm D; Johansson A; Aquilonius SM; Hellquist E; Lennernäs H; Askmark H Clin Neuropharmacol; 2012; 35(1):6-14. PubMed ID: 22094648 [TBL] [Abstract][Full Text] [Related]
16. Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease. Hauser RA; Ellenbogen AL; Metman LV; Hsu A; O'Connell MJ; Modi NB; Yao HM; Kell SH; Gupta SK Mov Disord; 2011 Oct; 26(12):2246-52. PubMed ID: 21755537 [TBL] [Abstract][Full Text] [Related]
17. Prolonged serum levodopa levels with controlled-release carbidopa-levodopa in the treatment of Parkinson's disease. Hutton JT; Albrecht JW; Román GC; Kopetzky MT Arch Neurol; 1988 Jan; 45(1):55-7. PubMed ID: 3276299 [TBL] [Abstract][Full Text] [Related]
18. Clinical and pharmacokinetic comparison of oral and duodenal delivery of levodopa/carbidopa in patients with Parkinson's disease with a fluctuating response to levodopa. Deleu D; Ebinger G; Michotte Y Eur J Clin Pharmacol; 1991; 41(5):453-8. PubMed ID: 1761073 [TBL] [Abstract][Full Text] [Related]